“Other Non-Operating Expenses years ended December 31 (in millions) 2025 2024 2023 Interest expense $ 2,893 $ 2,808 $ 2,224 Interest income (266) (648) (540) Interest expense, net $ 2,627 $ 2,160 $ 1,684 Net foreign exchange loss $ 58 $ 21 $ 146 Other expense, net 5,793 3,240 4,677 Interest expense in 2025 increased compared to 2024 primarily due to the impact of higher effective interest rates.”
“The increase is primarily due to share repurchases, higher taxes paid in connection with shares that were withheld from RSUs that vested during the period, as a result of an increase in the value of our common stock as compared to 2024, lower proceeds from option exercises, higher principal payments on term debt due to the payoff of the obligations outstanding under the Ares Credit Facility and related penalties, partially offset by the debt proceeds related to the JPM Credit Facilities.”
“AbbVie's global Imbruvica revenues decreased 25% for the three months ended March 31, 2026 primarily driven by unfavorable pricing and decreased demand in the United States, partially offset by increased collaboration revenues.”